Clinical trial
A Phase II, Open-label, Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis
NCT01730716 is registered in ClinicalTrials.gov with Neuralstem Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Open-label, Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis
- Lead sponsor
- Neuralstem Inc.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- May 31, 2013
- Completion date
- November 30, 2016
- Enrollment
- 18 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.